Physician profile
Eli Michael Robinson
NPI 1750144820
$2,050.93
in general payments reported to CMS, 2019-2025
21 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $817 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,050.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $659.71 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $219.62 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $151.90 | 2024-2025 | |
| Abbvie INC. | $121.10 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.00 | 2024-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $93.36 | 2024-2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $93.18 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $89.90 | 2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $76.77 | 2024-2025 | |
| Abbott Laboratories | $55.54 | 2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $51.47 | 2025 | Korlym |
| Abiomed | $47.30 | 2025 | |
| Sanofi-Aventis U.S. LLC | $44.55 | 2025 | |
| Alexion Pharmaceuticals, INC. | $41.16 | 2024-2025 | Strensiq |
| Daiichi Sankyo INC. | $38.25 | 2024 | Injectafer |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $33.92 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $28.35 | 2025 | Gemtesa |
| Astellas Pharma US INC | $23.92 | 2024 | Veozah |
| Noven Therapeutics, LLC | $23.09 | 2025 | Xelstrym |
| Merck Sharp & Dohme LLC | $20.34 | 2025 | Gardasil 9, Capvaxive |
| Phathom Pharmaceuticals, INC. | $18.50 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.